These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 10474088)

  • 1. Isoantibodies in immunoglobulin for intravenous use may cause erythrocyte sequestration.
    Shoham-Kessary H; Gershon H
    Vox Sang; 1999; 77(1):33-9. PubMed ID: 10474088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo administration of intravenous immunoglobulin (IVIg) can lead to enhanced erythrocyte sequestration.
    Kessary-Shoham H; Levy Y; Shoenfeld Y; Lorber M; Gershon H
    J Autoimmun; 1999 Aug; 13(1):129-35. PubMed ID: 10441177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of human intravenous immunoglobulin on canine monocytes and lymphocytes.
    Reagan WJ; Scott-Moncrieff C; Christian J; Snyder P; Kelly K; Glickman L
    Am J Vet Res; 1998 Dec; 59(12):1568-74. PubMed ID: 9858408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haemolysis after treatment with intravenous immunoglobulin due to anti-A.
    Morgan S; Sorensen P; Vercellotti G; Zantek ND
    Transfus Med; 2011 Aug; 21(4):267-70. PubMed ID: 21605202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemical treatment of anti-D results in improved efficacy for the inhibition of Fcgamma receptor-mediated phagocytosis.
    Foo AH; Ramkumar S; Helke S; Branch DR
    Transfusion; 2007 Dec; 47(12):2250-9. PubMed ID: 17714414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune complex-like moieties in immunoglobulin for intravenous use (i.v.Ig) bind complement and enhance phagocytosis of human erythrocytes.
    Shoham-Kessary H; Naot Y; Gershon H
    Clin Exp Immunol; 1998 Jul; 113(1):77-84. PubMed ID: 9697987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-red blood cell antibodies, free light chains, and antiphospholipid antibodies in intravenous immunoglobulin preparations.
    Sakem B; Matozan K; Nydegger UE; Weigel G; Griesmacher A; Risch L
    Isr Med Assoc J; 2013 Oct; 15(10):617-21. PubMed ID: 24266088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immunoglobulin-induced panel reactive antibody A reduction: not all preparations are created equal.
    Clark B; Cole JY; Wortley A; Toolan J; Stoves J; Newstead CG; Gooi HC
    Transplantation; 2003 Jan; 75(2):242-5. PubMed ID: 12548133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of cytokine modulation following therapeutic infusion of intravenous immunoglobulin or anti-red blood cell antibodies in a mouse model of immune thrombocytopenic purpura.
    Aubin E; Lemieux R; Bazin R
    Br J Haematol; 2007 Mar; 136(6):837-43. PubMed ID: 17341270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of physiologic autoantibody in the removal of senescent human red cells.
    Kay MM
    J Supramol Struct; 1978; 9(4):555-67. PubMed ID: 108480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro comparison of the complement-scavenging capacity of different intravenous immunoglobulin preparations.
    Spycher M; Matozan K; Minnig K; Zehnder R; Miescher S; Hoefferer L; Rieben R
    Vox Sang; 2009 Nov; 97(4):348-54. PubMed ID: 19656348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous immunoglobulins induce CD32-mediated platelet aggregation in vitro.
    Pollreisz A; Assinger A; Hacker S; Hoetzenecker K; Schmid W; Lang G; Wolfsberger M; Steinlechner B; Bielek E; Lalla E; Klepetko W; Volf I; Ankersmit HJ
    Br J Dermatol; 2008 Sep; 159(3):578-84. PubMed ID: 18565176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations.
    Altznauer F; von Gunten S; Späth P; Simon HU
    J Allergy Clin Immunol; 2003 Dec; 112(6):1185-90. PubMed ID: 14657880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of anti-cardiolipin antibodies and IVIg on annexin A5 binding to endothelial cells: implications for cardiovascular disease.
    Frostegård AG; Su J; von Landenberg P; Frostegård J
    Scand J Rheumatol; 2010; 39(1):77-83. PubMed ID: 20132075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitation of alloantibody concentration can predict patient sensitivity to intravenous immunoglobulin desensitization.
    Kimball PM; Owens A; Gibney E
    Transplantation; 2007 Dec; 84(11):1540-3. PubMed ID: 18091532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial.
    Jordan SC; Tyan D; Stablein D; McIntosh M; Rose S; Vo A; Toyoda M; Davis C; Shapiro R; Adey D; Milliner D; Graff R; Steiner R; Ciancio G; Sahney S; Light J
    J Am Soc Nephrol; 2004 Dec; 15(12):3256-62. PubMed ID: 15579530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous immunoglobulin G-mediated inhibition of T-cell proliferation reflects an endogenous mechanism by which IgG modulates T-cell activation.
    MacMillan HF; Lee T; Issekutz AC
    Clin Immunol; 2009 Aug; 132(2):222-33. PubMed ID: 19447680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenesis and mechanisms of antibody-mediated hemolysis.
    Flegel WA
    Transfusion; 2015 Jul; 55 Suppl 2(0):S47-58. PubMed ID: 26174897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of IgE production in vitro by intact and fragmented intravenous immunoglobulin.
    Zhuang Q; Mazer B
    J Allergy Clin Immunol; 2001 Aug; 108(2):229-34. PubMed ID: 11496239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of intravenous immunoglobulin to delay xenogeneic hyperacute rejection. An in vivo and in vitro evaluation.
    Gautreau C; Kojima T; Woimant G; Cardoso J; Devillier P; Houssin D
    Transplantation; 1995 Nov; 60(9):903-7. PubMed ID: 7491691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.